ticagrelor and Carcinoma--Lewis-Lung

Tumor cells can activate platelets, which in turn facilitate tumor cell survival and dissemination. Platelets inhibition or blocking platelet-tumor cell interactions has become a strategy to suppress tumor progression. In this study, we investigated the effect of ticagrelor, a new antiplatelet drug, on tumor cell proliferation and metastasis. Our results show that ticagrelor not only inhibits the proliferation, migration, and invasion of B16F10 and Lewis lung carcinoma cells but also induces platelet apoptosis. In addition, we find that apoptosis of the platelet cells is dose dependent. Further, the result of in-vivo experiments proved that ticagrelor treatment decreased the tumor metastasis. The results of this study demonstrate that ticagrelor may be a potential anti-tumor agent for tumor metastasis.

Topics: Animals; Antineoplastic Agents; Apoptosis; Blood Platelets; Carcinoma, Lewis Lung; Cell Movement; Cell Proliferation; Lung Neoplasms; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Platelet Aggregation Inhibitors; Ticagrelor